Scott T. Tagawa, MD, MS


Prostate Cancer Management: Future Directions in Care

May 25th 2022

Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.

Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

May 25th 2022

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC: Clinical Pearls and Practical Advice

May 19th 2022

Highlighting ongoing clinical trials in prostate cancer, experts share practical advice on optimal treatment strategies for community physicians.

Addressing Bone and Visceral Metastases in Metastatic CRPC

May 18th 2022

A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.

Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases

May 18th 2022

Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.

Emerging Targeted Therapies in mCRPC

May 12th 2022

Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.

Defining Unmet Needs in the Management of mCRPC

May 12th 2022

Experts share insight on the greatest unmet needs in treating patients with metastatic castration-resistant prostate cancer.

Selecting Among Novel Imaging Options in Metastatic CRPC

May 11th 2022

A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC: Utility of Imaging as a Biomarker

May 11th 2022

Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.

Ongoing PSMA-Targeted Radioligand Trials in mCRPC

May 5th 2022

Andrew J. Armstrong, MD, MSc, breaks down ongoing prostate cancer clinical trials looking at targeted radioligand therapies.

Metastatic CRPC: Considerations for Radiotherapy

May 5th 2022

Oliver Sartor, MD, considers the respective roles of Lu-PSMA-617 and radium-223 as radiotherapy in the setting of mCRPC.

DNA Alterations and Selection of PARP Inhibitors in mCRPC

May 4th 2022

Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.

Overview of Therapy for mCRPC: PARP Inhibitors

May 4th 2022

A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.

Potential Role of Lu-PSMA-617 in mCRPC

April 28th 2022

Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

VISION Trial: Lu-PSMA-617 in mCRPC

April 28th 2022

A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.

Interpreting Data From the ARASENS Trial in Metastatic HSPC

April 27th 2022

Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.

Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial

April 27th 2022

Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.

Role of Radium-223 in Treating mCRPC

April 21st 2022

Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.

Patient Factors in Selecting Therapy for mCRPC

April 21st 2022

Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.

Role of Micronized Abiraterone in Metastatic HSPC

April 20th 2022

Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.